Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original) A composition for treating premature ejaculation by pulmonary inhalation, said composition comprising an antidepressant.

Claim 2. (Original) A composition as claimed in claim 1, wherein the antidepressant is a tricyclic antidepressant.

Claim 3. (Currently amended) A composition as claimed in ~~either of the preceding~~ claim 1, wherein the composition comprises two or more antidepressants.

Claim 4. (Currently amended) A composition as claimed in ~~any one of the preceding claims~~ claim 1, wherein the composition comprises a further therapeutic agent, which is not an antidepressant.

Claim 5. (Original) A composition as claimed in claim 4, wherein the further therapeutic agent is also effective in treating PE.

Claim 6. (Currently amended) A composition as claimed in claim 4 ~~or claim 5~~, wherein the further therapeutic agent is a benzodiazepine.

Claim 7. (Currently amended) A composition as claimed in ~~any one of the preceding claims~~ claim 1, wherein the administration of the composition by pulmonary inhalation is not accompanied with the adverse side effects usually associated with the administration of the antidepressant.

Claim 8. (Currently amended) A composition as claimed in ~~any one of the preceding claims~~ claim 1, wherein the composition provides a dose of antidepressant of less than about 25mg~~, less~~

~~than about 20mg, less than about 15mg, less than about 10mg, less than about 5mg, less than about 2mg or less than about 1mg~~.

Claim 9. (Currently amended) A composition as claimed in ~~any one of the preceding claims~~ claim 1, wherein the composition provides an onset of the therapeutic effect within no more than 30 minutes~~, no more than 25 minutes, no more than 20 minutes, no more than 15 minutes, no more than 10 minutes, no more than 8 minutes, no more than 6 minutes, no more than 5, 4, 3 or 2 minutes, or no more than 1 minute~~, following pulmonary administration.

Claim 10. (Currently amended) A composition as claimed in ~~any one of the preceding claims~~ claim 1, wherein the composition is a dry powder composition.

Claim 11. (Original) A composition as claimed in claim 10, wherein the composition comprises particles of antidepressant having a mass median aerodynamic diameter of about 10μm or less.

Claim 12. (Original) A composition as claimed in claim 11, wherein the mass median aerodynamic diameter is about 5μm or less.

Claim 13. (Currently amended) A composition as claimed in ~~any one of claims 10 to 12~~ claim 10, wherein at least 90% of the antidepressant has a particle size of about 10μm or less.

Claim 14. (Original) A composition as claimed in claim 13, wherein at least 90% of the antidepressant has a particle size of about 5μm or less.

Claim 15. (Currently amended) A composition as claimed in ~~any one of claims 10 to 14~~ claim 10, wherein the composition further comprises an additive material.

Claim 16. (Original) A composition as claimed in claim 15, wherein the additive material is provided in an amount from about 0.15% to about 5% of the composition, by weight.

Claim 17. (Currently amended) A composition as claimed in claim 15 ~~or claim 16~~, wherein the

additive material is selected from the group consisting of leucine, magnesium stearate, lecithin, and sodium stearyl fumarate.

Claim 18. (Currently amended) A composition as claimed in ~~any one of claims 10 to 17~~ claim 10, wherein the composition further comprises an excipient material.

Claim 19. (Original) A composition as claimed in claim 18, wherein the excipient material is in the form of carrier particles having an average particle size of about 40 to about 70μm.

Claim 20. (Currently amended) A composition as claimed in ~~any one of claims 1 to 9~~ claim 1, wherein the composition comprises a solution pMDI formulation including a propellant, a solvent and water.

Claim 21. (Currently amended) A composition as claimed in ~~any one of claims 1 to 9~~ claim 1, wherein the composition is a suspension pMDI formulation including a propellant.

Claim 22. (Currently amended) A composition as claimed in claim 20 ~~or claim 21~~, wherein the propellant is selected from the group consisting of: HFA134a ~~and/or~~ HFA227 and a combination thereof.

Claim 23. (Currently amended) A method of treating premature ejaculation, the method comprising administering to a subject in need of such treatment a composition as claimed in ~~any one of the preceding claims~~ claim 1.

Claim 24. (Original) A method as claimed in claim 23, wherein the method does not cause the adverse side effects normally associated with the administration of the antidepressant.

Claims 25-26 (Canceled)

Claim 27. (Currently amended) A dry powder inhaler device comprising a composition as claimed in ~~any one of claims 1 to 22~~ claim 1.

Claim 28. (Original) A dry powder inhaler device as claimed in claim 27, wherein the inhaler is an active inhaler.

Claim 29. (Currently amended) A dry powder inhaler device as claimed in claim 27 ~~or 28~~, wherein the inhaler is a breath actuated inhaler device.

Claim 30. (Currently amended) The device of claim 27 comprising a [[A]] blister ~~for use in a dry powder inhaler device as claimed in any one of claims 27 to 29~~, wherein the blister contains the composition.

Claim 31. (Currently amended) ~~A composition as claimed in any of claims 1-22, a method as claimed in claim 23 or 24, a use as claimed in claim 25 or 26, an inhaler as claimed in any of claims 27-29, or a blister as claimed in claim 30~~, The method of claim 23, wherein ~~the~~ adverse side effects, if any, provoked by the administration of the composition by inhalation are such that they would easily be tolerated by an average recipient.

Claim 32. (New) A composition as claimed in claim 1, wherein the composition provides a dose of antidepressant of less than about 15mg.

Claim 33. (New) A composition as claimed in claim 1, wherein the composition provides a dose of antidepressant of less than about 5mg.

Claim 34. (New) A composition as claimed in claim 1, wherein the composition provides an onset of the therapeutic effect within no more than 20 minutes following pulmonary administration.

Claim 35. (New) A composition as claimed in claim 1, wherein the composition provides an onset of the therapeutic effect within no more than 10 minutes following pulmonary administration.

Claim 36. (New) A composition as claimed in claim 1, wherein the composition provides an onset of the therapeutic effect within no more than 5 minutes following pulmonary administration.

Claim 37. (New) A composition as claimed in claim 1, wherein the composition provides an onset of the therapeutic effect within no more than 1 minute following pulmonary administration.